IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. To learn more, visit www.isoplexis.com

Lupagen, Inc. is a privately held preclinical gene therapy company developing first-in-class gene delivery technologies for next generation CAR-T, gene editing and immunotherapy products based on its extracorporeal gene delivery platform. Lupagen’s platform harnesses standard apheresis-based systems customized for a diverse range of ex- vivo autologous cell and gene therapies that require targeted genetic or cellular modifications of targeted populations of a patient’s circulating peripheral blood mononuclear cells.

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. To learn more, please visit www.lunaphore.com

Lykan Bioscience is an innovative contract development and manufacturing services organization (CDMO) focused on cell-based therapies. With decades of biopharmaceutical industry experience, Lykan offers a full range of development and manufacturing services. The state-of-the-art, purpose-built facility offering eight independent manufacturing suites is uniquely designed to fully integrate cGMP principles and advanced software solutions to enable real-time testing and release of product. Six additional cGMP processing suites will be commissioned by the end of 2022 to support US/EU clinical and commercial manufacturing. Located in Hopkinton, Massachusetts, 25 miles southwest of downtown Boston and in the proximity of four international airports, Lykan Bioscience is ideally situated to deliver life-saving cell therapy treatments to patients on behalf of their partners. To learn more, please visit www.lykanbio.com

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions. The GeoMx® Digital Spatial Profiler combines the power of whole tissue imaging with gene expression and protein data. The CosMx™ Spatial Molecular Imager is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution. To learn more, please visit www.nanostring.com

Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Dive deeper at www.natera.com/oncology

NDA is a world leading regulatory drug & device development consultancy, supporting companies with their regulatory, pharmacovigilance, quality and strategic communication challenges across the US and Europe, from concept to commercialization. In 2020 the NDA team supported 1 in 5 of the medicinal products approved by the FDA and 42% of the medicinal products approved in Europe. To learn more, visit www.ndareg.com

Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data. Nucleai provides pharmaceutical companies, contract research organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making. For more information, please visit nucleai.ai

Oncimmune, a global leader in immunodiagnostics is focused on autoantibody profiling in immuno-oncology, autoimmune and infectious diseases. Through ImmunoINSIGHTS profiling services, we provide clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy. The headquarter is based in UK and also operates in Germany and USA.

Outpace Bio is pioneering the era of curative cell therapies with built-for-purpose function powered by protein design. With an initial focus on oncology, the Company is creating technologies that solve efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive potent and persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the specificity and safety necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. Outpace is based in Seattle, Washington. To learn more, visit outpacebio.com.

Palleon is a clinical-stage company pioneering drug development in glyco-immunology, a transformative field that shows that the immune system can be dysregulated by glycans. To learn more, please visit www.palleonpharma.com